Paradigm PeptideRetatrutide
Ordered Retatrutide from Paradigm Peptide? Mail in a sample (US only) and let us test it for free.
Test my supplyParadigm Peptide retatrutide looks low-concern under this purity-focused method; the score is held down mainly by confidence smoothing, not failed classifiable assays. Key caveats are a +15% overfill and recent no-label/no-batch records.
We investigated who actually operates Paradigm Peptide — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Paradigm Peptide rows.
Cancel anytime
About Paradigm Peptide test results from Finnrick
Paradigm Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 2 peptides and 18 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Paradigm Peptide peptides in this dataset are Retatrutide (8 tests), Tirzepatide (10 tests) and PT-141 (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 18 recent tests.
Ordered Retatrutide from Paradigm Peptide? Mail in a sample (US only) and let us test it for free.
Test my supply